TIGIT, which serves as the “braker” in immune checkpoint regulation, together with another “braker”, PD-1/PD-L1, may not be sufficient to activate the immune cells to kill tumor cells, especially in patients with advanced or high-burden tumors. Here, TIGIT is linked to neoplasm.